Premium
Venlafaxine‐Associated Vaginal Bleeding
Author(s) -
Linnebur Sunny A.,
Saseen Joseph J.,
Pace Wilson D.
Publication year - 2002
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.22.8.652.33219
Subject(s) - venlafaxine , discontinuation , medicine , vaginal bleeding , bupropion , depression (economics) , fluoxetine , venlafaxine hydrochloride , anesthesia , adverse effect , psychiatry , antidepressant , anxiety , serotonin , pregnancy , genetics , receptor , macroeconomics , pathology , biology , smoking cessation , economics
A 41‐year‐old amenorrheic woman started taking venlafaxine 37.5 mg/day for treatment of depression; 7 days later, she experienced vaginal bleeding, which ceased 1 day after she stopped taking the drug. On rechallenge with venlafaxine, she again experienced vaginal bleeding that resolved after discontinuation. We found no published reports describing vaginal bleeding associated with venlafaxine. However, premarketing and postmarketing data report similar adverse effects in patients taking the agent. In addition, several cases of menstrual irregularities have occurred with two other anti‐depressants: fluoxetine and bupropion. This case report supports previous surveillance data indicating that venlafaxine may cause vaginal bleeding.